CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）（FoxP3⁺ 和 CD8⁺）与肿瘤相关巨噬细胞在早期 HER2⁺ 乳腺癌中的预后和预测作用
英文原题：The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer.
查看英文原题
The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
在 HER2+ Luminal B 亚组中，高 FoxP3+TILs 与较短的 DFS 相关。高 CD8+mTILs/CD68+TAMs 比值似乎与曲妥珠单抗的显著疗效相关。
研究思路结论见上方概要
在HER2阳性（HER2+）乳腺癌中，TIL（肿瘤浸润淋巴细胞）（TILs）和肿瘤相关巨噬细胞（TAMs）可能影响HER2抗体曲妥珠单抗的疗效及患者的结局。在这个HER2+患者队列中，我们的目的是研究FoxP3+调节性TILs和CD8+细胞毒性TILs的数量，它们与CD68+和CD163+TAMs的相关性，以及所研究因素的预后和预测价值。
我们评估了2001年至2008年间接受手术的139例非转移性HER2+乳腺癌患者。采用热点法评估FoxP3+TIL计数（FoxP3+TILs），并利用数字图像分析从浸润边缘区域评估CD8+TIL计数（CD8+mTILs）。计算了CD8+mTILs与FoxP3+TILs之间以及CD8+mTILs与TAMs之间的比值。
FoxP3 + TILs与CD8 + mTILs彼此呈正相关（p<0.001）。FoxP3+TILs与CD68+和CD163+TAMs呈正相关（p 0.038），而CD8 + mTILs仅与CD68+TAMs相关（p<0.001）。在HER2 + 和激素受体阳性的Luminal B亚组中，高数量的FoxP3+TILs与较短的无病生存期（DFS）相关（54% vs. 79%，p = 0.040）。在高CD8 + mTILs/CD68 + TAMs比值的患者中，辅助曲妥珠单抗治疗的获益极为显著，接受或不接受曲妥珠单抗治疗的患者中，总生存期（OS）分别为84% vs. 33%（p = 0.003），乳腺癌特异性生存期（BCSS）分别为88% vs. 48%（p = 0.009）。
展开英文摘要原文
In HER2-positive (HER2 +) breast cancer, tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) may influence the efficacy of the HER2-antibody trastuzumab and the patient's outcome. In this HER2 + patient cohort, our aim was to study the numbers of FoxP3 + regulatory TILs and CD8 + cytotoxic TILs, their correlations with CD68 + and CD163 + TAMs, and the prognostic and predictive value of the studied factors.
We evaluated 139 non-metastatic HER2 + breast cancer patients operated between 2001 and 2008. The FoxP3+TIL count (FoxP3+TILs) was assessed using the hotspot method, and the CD8 + TIL count (CD8+mTILs) utilizing a digital image analysis from invasive margin areas. The ratios between CD8+mTILs and FoxP3+TILs as well as CD8+mTILs and TAMs were calculated.
FoxP3 + TILs and CD8 + mTILs correlated positively with each other (p<0.001). FoxP3+TILs had a positive correlation with CD68+and CD163+TAMs (p 0.038), while CD8 + mTILs correlated only with CD68+TAMs (p<0.001). In the HER2 + and hormone receptor-positive Luminal B subgroup, high numbers of FoxP3+TILs were associated with shorter disease-free survival (DFS) (54% vs. 79%, p = 0.040). The benefit from adjuvant trastuzumab was extremely significant among patients with a high CD8 + mTILs/CD68 + TAMs ratio, with overall survival (OS) 84% vs. 33% (p = 0.003) and breast cancer-specific survival (BCSS) 88% vs. 48% (p = 0.009) among patients treated with or without trastuzumab, respectively.
In the HER2 + Luminal B subgroup, high FoxP3 + TILs were associated with shorter DFS. A high CD8 + mTILs/CD68 + TAMs ratio seems to associate with impressive efficacy of trastuzumab.
论文信息
- 作者
- Jääskeläinen MM、Tiainen S、Siiskonen H、Ahtiainen M、Kuopio T、Rönkä A、Kettunen T、Hämäläinen K
- 第一作者单位
- Cancer Center, Kuopio University Hospital, Northern Savonia Healthcare Municipality, P.O.Box 100, 70029, Kuopio, Finland.Finland
- 通讯作者单位
- Cancer Center, Kuopio University Hospital, Northern Savonia Healthcare Municipality, P.O.Box 100, 70029, Kuopio, Finland. satu.tiainen@pshyvinvointialue.fi.Finland
- 期刊
- Breast cancer research and treatment2023 Sep
- 原文标识
- PubMed 37428418 · DOI 10.1007/s10549-023-07017-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →